Ultragenyx Pharmaceutical
Nasdaq RARE · Novato, CA
Works in Dermatology · Genetic & rare · GI & liver · Hematology · Metabolic & endocrine · Musculoskeletal · Neurology · Psychiatry · Renal & urogenital · Women's health
Ultragenyx Pharmaceutical is a clinical trial sponsor based in Novato, CA, listed as Nasdaq RARE. It has 19 active clinical trials with 2,202 planned participants, across 10 therapeutic areas. Since 2021 it has completed 15 trials and stopped 11 early.
Trial track record · since 2021
Financials · Nasdaq RARE
Pipeline · 19 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is lead sponsor of 19 active clinical trials on ClinicalTrials.gov, with 2,202 planned participants, in Dermatology, Genetic & rare, GI & liver, Hematology and other areas. Since 2021 it has completed 15 trials and stopped 11 early.
Ultragenyx Pharmaceutical is based in Novato, CA and is listed as Nasdaq RARE. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Ultragenyx Pharmaceutical; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-14.
Approve Suite is not affiliated with Ultragenyx Pharmaceutical.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.